I5T-MC-AACQ: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502268-18-00

Acronym

I5T-MC-AACQ

Enrollment

Registered

2023-04-07

Start date

Unknown

Completion date

2024-03-19

Last updated

2023-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurocognitive Disorders, Central Nervous System Diseases, Neurodegenerative Diseases, Nervous System Diseases, Dementia, Alzheimer’s Disease, Brain Diseases, Mental Disorders

Brief summary

Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)

Interventions

DRUGNeuraceq 300 MBq/mL solution for injection

DRUGSODIUM CHLORIDE

DRUGDonanemab

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participants with Any Occurrence of Amyloid-Related Imaging Abnormality-Edema/Effusion (ARIA-E)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026